The Artificial Pancreas: A Race To The Finish

The first fully functional artificial pancreas for patients with diabetes could be ready for regulatory submission in the next few years. Medtronic has achieved notable success in this area to date, but positive clinical studies have put J&J in a good position as well, and the medical community is watching closely as the major developments in this groundbreaking endeavor continue to move forward.

What originally started as a scientific hypothesis supported by a small group of believers has grown into a competitive project now involving some of the biggest names in the diabetes device space. The quest to develop a functioning artificial pancreas system (APS) is moving into the later stages, and if the current pace continues, it is possible a product could be ready for regulatory submission in the next few years. A great deal of enthusiasm and support for this milestone is coming from the business and medical communities, which have seen this technology take tremendous leaps forward in the last 10 years, moving from concept to reality. The development and refinement of insulin delivery pumps, continuous glucose monitors (CGMs), and sophisticated computer algorithms all are credited as major factors in this progress, but improvements in those elements also have been spurred along by a business environment that has supported the right balance of competition and cooperation in one of the most interesting races to see who will be first-to-market.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from In Vivo

Podcast: Ochre Bio’s Approach To Precision Medicine In Liver Treatment

 
• By 

Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.

Richard DiMarchi On The GLP-1 Revolution: An Overnight Success After 40 Years

 

As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.

Rising Leaders 2025: João Ribas On Building At The Intersection Of Science And Business

 
• By 

João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.